7MW4911 is an investigational CDH17-targeting ADC developed using Mabwell’s proprietary IDDC™ platform. Its highly optimized structure integrates three key elements: Mab0727: A highly specific CDH17 ...

Advances in instruments and tools, as well as focused collaborations, improve accuracy and extend the range of applications.

A recent meta-analysis reveals no link between pathologic complete response and long-term survival in rectal cancer, challenging its use as a surrogate endpoint.

Parents of boys with Duchenne muscular dystrophy weigh in on drug innovation and medical regulation.

This week on "The Readout LOUD," STAT's biotech reporters parse what Vinay Prasad's ouster means for biotech and the FDA.

SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of ...

We recently compiled a list of 11 Best Future Stocks to Buy Now. Denali Therapeutics Inc. stands sixth on our list among the ...

Shipment of delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), will resume following a ...

But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...

Orr Inbar, CEO and co-founder of QuantHealth, unpacks the growing frustration over drug prices and the misperceptions fueling distrust in the pharmaceutical industry. With clinical trials now more ...

FDA Commissioner Marty Makary said the FDA’s review process will not slow down despite layoffs at the Department of Health ...